Full Title
A Multi-Site Break Through Cancer Pilot Study Testing the Feasibility and Safety of Therapeutic Intervention for Patients with High-risk Clonal Cytopenia of Undetermined Significance (CCUS)Purpose
Researchers want to see if ASTX727 is practical and safe for people with high-risk clonal cytopenia of undetermined significance (CCUS). With CCUS, there is a mutation (change) in one or more of the genes that help blood cells develop. People with CCUS have low levels of certain kinds of blood cells. CCUS can lead to precancerous conditions such as myelodysplastic syndrome or blood cancers such as acute myeloid leukemia.
ASTX727 is a combination of two drugs: cedazuridine and decitabine. Cedazuridine protects decitabine from being broken down in the body too quickly. This protection allows decitabine to fix DNA in blood cells. ASTX727 may help the body make healthy blood cells and reduce the number of unhealthy cells that lead to cancer. It is taken orally (by mouth).
Who Can Join
To join this study, there are a few conditions. You must:
- Have CCUS that places you at high risk of developing a blood cancer.
- Not have had anti-cancer treatment within 6 months of taking ASTX727.
- Be able to walk and do routine activities for more than half the time you are awake.
- Be age 18 or older.
Contact
For more information about this study or to see if you can join, please call Dr. Tamanna Haque’s office at 646-608-4166.